)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Addex Therapeutics
Addex Therapeutics (ADXN) investor relations material
Addex Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Sep, 2026
Executive summary
Raised $2.8 million via ATM facility, extending cash runway into Q4 2027 and supporting advancement of the in-house GABAB cough program toward clinical development.
Regained full rights to the GABAB PAM program from Indivior, enabling broad development opportunities across multiple indications.
Retained 20% equity in Neurosterix, which is advancing its M4 PAM program for schizophrenia with phase I data expected in Q4 2026.
Divested discovery platform to Neurosterix, retaining access to R&D staff at zero cost.
Pipeline includes dipraglurant for brain injury recovery, ADX-71149 for new indications, and ongoing discussions with potential partners.
Financial highlights
Net loss for H1 2026 was CHF 3.5 million, slightly higher than CHF 3.4 million in H1 2025.
Cash and cash equivalents at June 30, 2026, were CHF 0.8 million, down from CHF 1.6 million at year-end 2025.
Operating loss for H1 2026 was CHF 1.1 million, down from CHF 1.3 million in H1 2025, mainly due to reduced outsourced R&D.
Share of net loss from Neurosterix was CHF 2.3 million in H1 2026, up from CHF 2.1 million in H1 2025.
Raised CHF 2.3 million post-period through share sales.
Outlook and guidance
Cash runway secured into Q4 2027 following recent fundraising, but material uncertainty remains regarding going concern due to the need for additional capital.
IND filing planned for SUD program; IND-enabling studies for cough program pending financing.
Neurosterix's NTX-253 phase I data expected in Q4 2026; backup M4 PAM and mGlu7 NAM programs advancing.
Preparing dipraglurant for phase II in post-stroke recovery.
Exploring new indications and potential partnerships for ADX-71149 and mGlu2 PAM program.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Addex Therapeutics
- Neurosterix spin-out and pipeline progress strengthen position, but new funding is needed for clinical trials.ADXN
H2 2024 - Net loss reached CHF 1.7 million as pipeline advanced and cash reserves declined.ADXNQ1 2026
- Net loss widened to CHF 6.8 million as clinical and strategic initiatives advanced.ADXNH2 2025
- Offering up to $150M in shares/ADSs to advance a novel drug pipeline for unmet medical needs.ADXNRegistration Filing
- Net loss of CHF 4.9 million and cash runway to mid-June 2026 highlight urgent funding needs.ADXNQ3 2025
- Major pipeline advances and a CHF 3.3m net loss; cash runway through mid-June 2026, funding needed.ADXNH1 2025
- Net profit of CHF 8.3 million driven by Neurosterix Transaction and GABA-B PAM progress.ADXNQ3 2024
- Net profit of CHF 9.8 million in H1 2024 driven by Neurosterix Transaction and cost reductions.ADXNH1 2024
- Divested platform for CHF 5M and 20% stake, advancing programs toward IND studies.ADXNQ1 2024
Next Addex Therapeutics earnings date
Q3 20269 Nov, 2026
Addex Therapeutics
Next Addex Therapeutics earnings date
Q3 20269 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of small molecule therapies for neurological disorders. The company specializes in allosteric modulators, a drug discovery approach aimed at targeting specific receptors in the central nervous system to treat conditions such as Parkinson’s disease, epilepsy, and schizophrenia. Addex conducts clinical and preclinical research to advance its pipeline of investigational treatments. The company is headquartered in Geneva, Switzerland, and its shares are listed on the SIX Swiss Exchange.